Jacob Schachter – Research output — Tel Aviv University

View Scopus Profile

Research activity per year

If you made any changes in Pure these will be visible here soon.

156 Article
8 Review article
4 Letter
3 Editorial
More
- 1 Conference contribution
- 1 Comment/debate

1 results

Filter

2022
Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))
Hughes, B. G. M., Munoz-Couselo, E., Mortier, L., Bratland, Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. & Grob, J. J., Aug 2022, In: Annals of Oncology. 33, 8, p. 853 1 p.
Research output: Contribution to journal › Comment/debate

Open Access